Tagged with P

Asia-Pacific The latest from Southeast Asian pharma, including soaring output in Singapore, tax breaks for research in Indonesia, Thai firm Factorytalk’s UK expansion, and the potential for a Russian COVID-19 vaccine manufacturing facility in the Philippines.   Singapore Factory Output Surges At Fastest Pace In Nine Years On Pharma Boost (Business…

Global Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park highlights key takeaways from the BIOJapan 2020 conference on why San Diego offers a good example of what it takes to be a leader in the innovative life science sector.   Over the past two decades, drug discovery has undergone…

UK When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left behind in terms of alignment with the world’s top regulatory bodies. Perhaps cognizant of this, the UK regulatory agency for…

China RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history by becoming the largest biotech IPO to date globally in 2020. It is also one of the biggest IPOs of…

China A roundup of the latest from Chinese pharma, including Green Valley’s upcoming US trial for an Alzheimer’s drug inspired by algae; Samsung Biologics expansion in China; Fosun Pharma’s halt to the development of a COVID-19 vaccine; and CAR-T biotech JW Therapeutics raising USD 300m in its IPO on the Hong…

Switzerland Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing attractiveness of Switzerland as a pharmaceutical investment destination.   Attractive conditions must be maintained both for the large pharmaceutical companies – which are well established in Switzerland, but for which the…

Norway Dan Schneider discusses the continuing Norwegian identity of Photocure, despite its increasingly global footprint, the company’s strategy, and his background within the life sciences sector.    We are a flagbearer for all Norwegian life sciences firms moving from development to commercialisation and a prime example of what the future could…

Norway John-Arne Røttingen, CEO of The Research Council of Norway shares his career journey from academia to industry, outlines his new role as Norway’s Global Health ambassador and gives his thoughts on Norway’s biotech and life sciences future.    On a country by country basis, Norway has had the highest proportion…

USA In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory Committee’s meeting on November 6 2020, what it means for that Aducanumab, and the impact on next-generation AD treatments.   November 6 could prove to be…

Global Dr Ann Aerts, head of the Novartis Foundation, highlights how the COVID-19 crisis has thrust artificial intelligence in healthcare into the limelight, and makes three bold predictions for the future of the field, especially in emerging countries.   As a true believer in the power of technology to transform health,…

Switzerland Alan Knox of Primex Pharmaceuticals explains how the COVID-19 pandemic has thrust the anaesthesia field back into the global spotlight, the benefits of incremental innovation in anaesthesia, and why having a Swiss headquarters is advantageous.   Up until COVID-19, Anaesthesia was incredibly underrepresented and undervalued as a therapeutic class. However,…

China While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in 2003! Gendicine® was a gene therapy for the treatment of haemophilia B. While China mostly lost the advantage of that…